GE Healthcare
GE Healthcare offers $1.06B for trio of Thermo Fisher lifesciences units
CareFusion closes Vital Signs purchase
CareFusion (NYSE:CFN) said it completed a deal with GE Healthcare (NYSE:GE) to acquire Vital Signs for $500 million.
FDA issues warning on Vital Signs’ anesthesia devices
Medtech trends: The most talked about device makers in November 2013
GE Healthcare lands FDA approval for Optison contrast agent
GE Healthcare (NYSE:GE) said it received pre-market approval from the FDA to begin in-house manufacturing of its Optison imaging agent.
Optison (or Perflutren Protein-Type A Microspheres Injectable Suspension) is a contrast agent designed to improve visualization of the heart’s left ventricle.